Bayer AGBSE:BAYN +2.05%74 PB Ratio is 1.36 as of Jun. 25, 2026, which is 6% below its 10-year median of 1.45. GuruFocus rates BSE:BAYN with a GF Score™ of 74/100 and a GF Value™ of lei139.17 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 922 Drug Manufacturers companies, Bayer AG ranks better than 64.53% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Bayer AG's share price is lei209.00. Bayer AG's Book Value per Share for the quarter that ended in Mar. 2026 was lei153.60. Hence, Bayer AG's PB Ratio of today is 1.36.
The historical rank and industry rank for Bayer AG's PB Ratio or its related term are showing as below:
BSE:BAYN'
s PB Ratio Range Over the Past 10 Years
Min: 0.58 Med: 1.45 Max: 3.57
Current: 1.37
During the past 13 years, Bayer AG's highest PB Ratio was 3.57. The lowest was 0.58. And the median was 1.45.
BSE:BAYN's PB Ratio is ranked better than 64.53% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.855
vs BSE:BAYN: 1.37
During the past 12 months, Bayer AG's average Book Value Per Share Growth Rate was -11.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -12.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -3.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -2.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Bayer AG was 22.30% per year. The lowest was -13.90% per year. And the median was 1.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Bayer AG PB Ratio Related Terms
Bayer AG PB Ratio Historical Data
* Premium members only.
The historical data trend for Bayer AG's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Bayer AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bayer AG PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bayer AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bayer AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Bayer AG's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Bayer AG (BSE:BAYN) has a PB Ratio of 1.36 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bayer AG and its competitors. This is near median its historical median of 1.45. Over the past decade, Bayer AG's PB Ratio has ranged from 0.58 to 3.57. According to the industry distribution chart, Bayer AG ranks #327 out of 922 companies in the Drug Manufacturers industry, placing it in the top 35.5%.
Is Bayer AG's PB Ratio too high?
Bayer AG's current PB Ratio of 1.36 is near median its 10-year median of 1.45. Over the past 10 years, this metric has ranged from a low of 0.58 to a high of 3.57. The Drug Manufacturers industry median PB Ratio is 1.86. Bayer AG's value of 1.36 is 26.7% below this industry median. Based on the distribution chart, Bayer AG ranks #327 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bayer AG has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #327 out of 922 companies for PB Ratio. This puts Bayer AG in the upper half of its industry. The industry median PB Ratio is 1.86. Bayer AG's value of 1.36 is 26.7% below this benchmark. Historically, Bayer AG's own PB Ratio has ranged from 0.58 to 3.57 over the past decade. While the company's 10-year median is 1.45 vs. the industry median of 1.86, Bayer AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bayer AG's current PB Ratio of 1.36 is 26.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bayer AG and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bayer AG's current PB Ratio is 1.36, which is near median its own 10-year median of 1.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (BSE:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is lei139.17, compared to a current price of lei209.00 — trading 50.2% above its estimated fair value. The current PB Ratio is 1.36, which is near median its 10-year median of 1.45 and 26.7% below the Drug Manufacturers industry median of 1.86. Bayer AG's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Bayer AG (BSE:BAYN), the current PB Ratio is 1.36 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bayer AG (BSE:BAYN) Overvalued in 2026?
Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued.
The current stock price of lei209.00 is trading 50.2% above its estimated GF Value™ of lei139.17.
GuruFocus considers Bayer AG to be Significantly Overvalued.
Key valuation signals for BSE:BAYN:
PB Ratio: 1.36 (near median its 10-year median of 1.45)
GF Value™: lei139.17 vs. price of lei209.00 (50.2% above fair value)
Industry Position: 26.7% below the Drug Manufacturers median (#327 of 922)
No single metric tells the full story. See the BSE:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
74GF Score
Get the complete analysis for BSE:BAYN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:BAYN has been successfully added to your 
